Coronavirus vaccine - Neovii Biotech
Alternative Names: COVID-19 vaccine - Neovii BiotechLatest Information Update: 28 Jun 2024
At a glance
- Originator Neovii Biotech
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for research development in COVID-2019-infections in Germany (Parenteral)
- 12 May 2020 Coronavirus vaccine - Neovii Biotech is available for licensing as of 17 May 2020. https://neovii.com/research-development/
- 12 May 2020 Neovii in-licenses patented technology from the Tel Aviv University